医学
吉西他滨
膀胱癌
抗代谢物
肿瘤科
化疗
佐剂
癌症
临床试验
内科学
毒性
疾病
作者
Katrin Schlack,Martin Boegemann,Julie Steinestel,Andres Jan Schrader,Laura‐Maria Krabbe
标识
DOI:10.1586/14737140.2016.1143777
摘要
Bladder cancer is a common type of cancer with an estimated incidence of more than 70,000 patients and had a mortality of 16,000 patients in the US in 2015. In more than 70% of cases the disease is diagnosed at the non-muscle invasive stage. However, muscle invasive or metastatic stages need multimodal treatment strategies including surgical treatment and chemotherapy in a neoadjuvant, adjuvant or palliative setting. Gemcitabine is a pyrimidine antimetabolite that has shown efficacy when used systemically in bladder cancer with only mild toxicity compared to other chemotherapeutic agents. This article aims to summarize the results of clinical trials in monotherapeutic, combined or sequential treatment strategies, especially considering efficacy and safety of the different therapeutic regimes.
科研通智能强力驱动
Strongly Powered by AbleSci AI